We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure
News

Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure

Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure
News

Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quark Pharmaceuticals, Inc. has announced the presentation of  positive results from preclinical efficacy studies for its systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF).

In the study, rats treated with a single bolus injection of rat AKIi-5, Quark's siRNA compound targeting the p53 gene, were significantly protected from ischemia/reperfusion-induced acute kidney injury. The compound was most efficacious when administered within a well-determined time window of 2-4 hours post injury.

The study also proved that AKIi-5 has a favorable drug disposition (PK) profile, with short local exposure predominantly to the kidney-exhibiting rapid clearance of the drug post-administration. Quark's preclinical studies to date also indicate that AKIi-5 has a favorable safety profile, with a therapeutic index (toxic dose/effective dose) in rats greater than 250.

Elena Feinstein, M.D., Ph.D., the Company's Chief Scientific Officer, presented the results of the preclinical efficacy studies in a poster session at the Beyond Genome 2007 conference in San Francisco, CA. Quark's poster presentation was based on unpublished data.

The studies were performed in collaboration with Bruce A. Molitoris, M.D., Director of the Division of Nephrology and Professor of Medicine at Indiana University School of Medicine, and lead academic investigator in the Quark program.

Advertisement